B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction

DJ van Veldhuisen, GCM Linssen, T Jaarsma… - Journal of the American …, 2013 - jacc.org
Objectives : This study sought to determine the prognostic value of B-type natriuretic peptide
(BNP) in patients with heart failure with preserved ejection fraction (HFPEF), in comparison …

The effects of positive psychology interventions on well-being and distress in patients with cardiovascular diseases: a systematic review and Meta-analysis

KJM Tönis, JT Kraiss, GCM Linssen… - Journal of psychosomatic …, 2023 - Elsevier
… Declarations of interest: The third author (GCM Linssen) works as cardiologist for the funder
(Ziekenhuisgroep Twente), but declares that this had no influence on the work presented in …

A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE …

…, MG Stoel, JHW Louwerenburg, GCM Linssen… - Journal of the American …, 2012 - jacc.org
Objectives : The aim of this study was to compare the safety and efficacy of Resolute
zotarolimus-eluting stents (ZES) (Medtronic Cardiovascular, Santa Rosa, California) with Xience V …

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

…, JCA Hoorntje, JA Kragten, AH Liem, GCM Linssen… - Lancet, 1999 - edoc.mdc-berlin.de
BACKGROUND: Metoprolol can improve haemodynamics in chronic heart failure, but
survival benefit has not been proven. We investigated whether metoprolol controlled release/…

Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary …

…, M Hartmann, P Zocca, GCM Linssen… - The Lancet, 2016 - thelancet.com
Background In patients with coronary artery disease, treated with durable polymer-coated
drug-eluting stents, the life-long presence of the polymer might delay arterial healing. Novel …

Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study

…, A Norhammar, H Haller, GCM Linssen… - Diabetes, obesity …, 2020 - Wiley Online Library
Aims To examine the manifestation of cardiovascular or renal disease (CVRD) in patients
with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated …

Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial

…, MH Van den Heuvel, CA Da Fonseca, GCM Linssen… - The Lancet, 2023 - thelancet.com
Background The effect of haemodynamic monitoring of pulmonary artery pressure has
predominantly been studied in the USA. There is a clear need for randomised trial data from …

Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a …

…, FHAF de Man, MG Stoel, MM Löwik, GCM Linssen… - The Lancet, 2014 - thelancet.com
Background Third-generation, permanent-polymer-based drug-eluting stents with novel,
flexible designs might be more easily delivered than previous generations of stents in complex …

Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction

GCM Linssen, M Rienstra, T Jaarsma… - European journal of …, 2011 - Wiley Online Library
Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and
preserved left ventricular ejection fraction - Linssen - 2011 - European Journal of Heart …

Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction

…, U Dahlström, JJ Brugts, GCM Linssen… - European journal of …, 2021 - Wiley Online Library
Aims We aimed to derive and validate clinically useful clusters of patients with heart failure
with preserved ejection fraction (HFpEF; left ventricular ejection fraction ≥50%). Methods and …